An Expanded Phase1/2a Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Immunogenicity, and Viral Shedding of MEDI-560, A Live, Attenuated Recombinant Parainfluenza Virus Type 3 (PIV3) Vaccine, Administered Intranasally to Healthy Infants 1 to <12 Months of Age.

Trial Profile

An Expanded Phase1/2a Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Immunogenicity, and Viral Shedding of MEDI-560, A Live, Attenuated Recombinant Parainfluenza Virus Type 3 (PIV3) Vaccine, Administered Intranasally to Healthy Infants 1 to <12 Months of Age.

Discontinued
Phase of Trial: Phase I/II

Latest Information Update: 29 Dec 2011

At a glance

  • Drugs MEDI 560 (Primary)
  • Indications Parainfluenza virus infections
  • Focus Adverse reactions; Pharmacodynamics
  • Most Recent Events

    • 20 Jul 2011 Results published in the Vaccine.
    • 03 May 2011 Results presented at the 2011 Annual Meeting of the Pediatric Academic Societies.
    • 02 Jul 2010 Status changed from suspended to active, no longer recruiting as reported by ClinicalTrials.gov (NCT00508651).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top